Synapse - Works

Results (5608)

VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of (177)Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Sartor, A. O.; Morris, M. J.; Krause, B. J.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis

Meeting Abstract

Sartor, A. O.; Armstrong, A. J.; Ahaghotu, C.; McLeod, D. G.; Cooperberg, M. R.; Penson, D. F.; Kantoff, P. W.; Vogelzang, N. J.; Hussain, A.; Pieczonka, C. M.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Examination of the additive value of CTC biomarkers of heterogeneity (Het) and chromosomal instability to nuclear-localized (nl) AR-V7+CTCs in prediction of poor outcomes to androgen receptor signaling inhibitor (ARSi) in metastatic castration resistant prostate cancer (mCRPC)

Meeting Abstract

Scher, H. I.; Schonhoft, J.; Graf, R. P.; Jendrisak, A.; Barnett, E.; Jayaram, A.; Winquist, E.; Landers, M.; Wang, Y.; Allan, A. L.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

CTC versus biopsy tissue sequencing: A concordance analysis of genomic copy number profile from mCRPC patients (pts)

Meeting Abstract

Scher, H. I.; Lee, J.; Dago, A. E.; Barnett, E.; Sutton, R.; Carbone, E.; Schreiber, N. A.; Hullings, M.; Ebrahim, N.; Landers, M. A.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase Ill trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma

Meeting Abstract

Rosenberg, J. E.; Ballman, K. V.; Halabi, S.; Watt, C.; Hahn, O. M.; Steen, P. D.; Dreicer, R.; Flaig, T. W.; Stadler, W. M.; Sweeney, C.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Atezolizumab (atezo) plus bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis

Meeting Abstract

Rini, B. I.; Motzer, R. J.; Powles, T.; McDermott, D. F.; Escudier, B.; Donskov, F.; Hawkins, R. E.; Bracarda, S.; Bedke, J.; De Giorgi, U.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Molecular profiling of ER plus metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors

Meeting Abstract

Razavi, P.; dos Anjos, C. H.; Brown, D. N.; Qing, L.; Ping, C.; Herbert, J.; Colon, J.; Liu, D.; Mao, M.; Norton, L.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

IMPACT: Immunotherapy in patients with metastatic cancers and CDK12 mutations

Meeting Abstract

Reimers, M. A.; Abida, W.; Chou, J.; George, D. J.; Heath, E. I.; McKay, R. R.; Pachynski, R. K.; Zhang, J.; Choi, J. E.; Feng, F. Y.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

An open label phase 1/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration resistant prostate cancer

Meeting Abstract

Rathkopf, D. E.; Saleh, M. N.; Tsai, F. Y. C.; Bilen, M. A.; Rosen, L. S.; Gottardis, M.; Infante, J. R.; Adams, B. J.; Liu, L.; Theuer, C. P.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Pal, S. K.; McDermott, D. F.; Atkins, M. B.; Escudier, B.; Rini, B. I.; Motzer, R. J.; Fong, L.; Joseph, R. W.; Oudard, S.; Ravaud, A.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save